In 2019, it was approved for clinical use in patients with advanced HR-positive and PIK3CA-mutant breast cancer, in combination with fulvestrant, a selective estrogen receptor degrader [153,158,159]. The gene discussed is PIK3CA; the disease is breast carcinoma.